Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Hepatitis C 1Hepatitis B 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

entecavir 9Tenofovir 3Lamivudine 3lenvatinib 2Sorafenib 2Hepatitis B Vaccines 2tenofovir alafenamide 1polysaccharide MGN3 1peginterferon alfa-2b 1navitoclax 1menatetrenone 1lens intermediate filament proteins 1human papillomavirus vaccine, L1 type 16, 18 1adefovir 1Ultrasonography 1Tumor Necrosis Factor-alpha 1Tetanus Toxoid 1Telbivudine 1Standard of Care 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Polymorphism, Genetic 1Pneumococcal Vaccines 1PHY 906 1Nivolumab 1Measles-Mumps-Rubella Vaccine 1Hypothermia, Induced 1Heptavalent Pneumococcal Conjugate Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hepatitis B × menatetrenone × Clear all
NCT00165633 2008-12-09

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Eisai Inc.

Phase 2/3 Terminated
540 enrolled
Gastrointestinal

Carcinoma, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡